Evidence map›Paper›PMID 26191146›Full record

ArticleInternational journal of clinical and experimental pathology2015

Prognostic value of Musashi-1 in endometrioid adenocarcinoma.

Li Ma, Yan-Li Xu, Wen-Jing Ding, Hong-Fang Shao, Yin-Cheng Teng

Open access · greenAbstract read
In one paragraph

Article in International journal of clinical and experimental pathology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Role of the RNA-binding protein family in gynecologic cancers.American journal of cancer research · 2023
    Review
  6. Article
  7. Review
  8. Review
  9. Prognostic molecular biomarkers in endometrial cancer: A review.Journal of cancer research & therapy · 2019
    Article
  10. Endometrial Stem Cell Markers: Current Concepts and Unresolved Questions.International journal of molecular sciences · 2018
    Review
  11. Musashi RNA-Binding Proteins as Cancer Drivers and Novel Therapeutic Targets.Clinical cancer research : an official journal of the American Association for Cancer Research · 2017
    Review
  12. MiR-330-3p inhibits gastric cancer progression through targeting MSI1.American journal of translational research · 2016
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Li MaDepartment of Obstetrics and Gynecology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital Shanghai, China.
Yan-Li XuDepartment of Obstetrics and Gynecology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital Shanghai, China.
Wen-Jing DingDepartment of Obstetrics and Gynecology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital Shanghai, China.
Hong-Fang ShaoDepartment of Obstetrics and Gynecology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital Shanghai, China.
Yin-Cheng TengDepartment of Obstetrics and Gynecology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital Shanghai, China.
Shanghai Sixth People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsMusashi-1, a RNA-binding protein, is suggested to be a cancer stem cell-related marker; its high level of protein expression is reported to be associated with high histological grade in some tumors. The aim of this study was to investigate the prognostic value of Musashi-1 in patients with endometrioid adenocarcinoma (EAC).

methodsWe examined the Musashi-1 mRNA expression level in 35 fresh EAC tissue samples and 15 normal endometrium samples by real-time RT-PCR, and its protein expression level in 148 paraffin EAC tissue samples and 20 paraffin normal endometrium samples by immunohistochemistry. The correlation between Musashi-1 and overall survival (OS) used Cox proportional hazards regression. The prognostic accuracy of Musashi-1 compared with other clinicopathological risk factors by logistic regression. Furthermore, we examined whether Musashi-1 expression is correlated with another cancer stem cell marker CD133 by real-time RT-PCR.

resultsMusashi-1 mRNA expression of EAC is 2.8-fold higher than that of normal endometrium (P=0.0009). Musashi-1 protein expression level is correlated with tumor stage, grade and vascular invasion. Patients with higher protein expression level of Musashi-1 are associated with poor survival rate than those with negative or low level of expression (HR=2.073, P=0.001). The area under the curve (AUC) for Musashi-1 is 0.8, which is higher than other clinicopathological factors (P=0.000). In addition, Musashi-1 mRNA expression seems to be closely correlated with CD133 expression (r=0.7167, P<0.0001).

conclusionsOur results suggest high level of Musashi-1 protein expression is associated with poor survival in EAC patients, which may be an independent prognostic factor for EAC.

Indexed as

AC133 AntigenAdultAgedAged, 80 and overAntigens, CDArea Under CurveBiomarkers, TumorCarcinoma, EndometrioidEndometrial NeoplasmsFemaleGene Expression Regulation, NeoplasticGlycoproteinsHumansImmunohistochemistryKaplan-Meier EstimateLogistic ModelsAC133 AntigenAntigens, CDBiomarkers, TumorGlycoproteinsMSI1 protein, humanNerve Tissue ProteinsPeptidesPROM1 protein, humanRNA-Binding ProteinsRNA, Messengerendometrioid adenocarcinomaMusashi-1prognosis

Identifiers

PMID26191146
PMCPMC4503018
OpenAlexW2409818384

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.